I期非小细胞肺癌治疗趋势:肺叶切除率下降,亚肺叶切除与SBRT上升
该研究基于美国国家癌症数据库1998至2012年临床I期非小细胞肺癌患者数据,分析治疗模式变化。共分析357,490例患者,发现肺叶切除率从55%降至50%,亚肺叶切除从12%升至17%,立体定向体部放疗自2003年出现后至2012年升至6.6%,未治疗患者比例稳定在约7%。
要点
- I期非小细胞肺癌肺叶切除率15年间从55%降至50%。
- 亚肺叶切除率从12%升至17%,SBRT至2012年达6.6%。
- 未治疗患者比例稳定在约7%,未因替代疗法增多而下降。
核心结论
- I期非小细胞肺癌中肺叶切除率下降,亚肺叶切除和立体定向体部放疗率上升。
- 替代疗法普及未使未治疗患者比例下降,未治疗率稳定在约7%。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库1998至2012年临床I期非小细胞肺癌患者。
- 排除以化疗为首程治疗及病理IV期患者后,最终分析357,490例。
主要发现
- 立体定向体部放疗首现于2003年,至2012年占所有治疗患者的6.6%(2063例)。
- 肺叶切除率从1998年55%降至2012年50%(P < .001)。
- 亚肺叶切除率从12%升至17%(P < .001),解释了肺叶切除下降的大部分。
- 未治疗患者比例稳定在约7%(P = .283)。
- 15年间I期非小细胞肺癌诊断数量稳步增加。
临床怎么用
- 临床I期非小细胞肺癌治疗选择呈现多元化,肺叶切除仍是主要方式但比例下降。
- 高危患者可考虑亚肺叶切除或立体定向体部放疗作为替代。
- 需关注仍有约7%患者未接受治疗,替代疗法普及未改善治疗覆盖率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Stage I non-small cell lung cancer traditionally is treated with lobectomy. Sublobar resection and stereotactic body radiation therapy provide alternative treatments for higher-risk groups. The purpose of this study was to determine the national treatment trends for stage I lung cancer. METHODS: The National Cancer Database was queried for patients with clinical stage I non-small cell lung cancer between 1998 and 2012. Patients were compared across treatment groups, and trends in treatment and disease were evaluated over the 15-year time period. RESULTS: The National Cancer Database contained 369,931 patients with clinical stage I non-small cell lung cancer. After removing patients who received chemotherapy as a first course of treatment and patients with pathologic stage IV, 357,490 patients were analyzed. The first recorded cases of stereotactic body radiation therapy are in 2003 and rapidly increased to 6.6% (2063) of all patients treated in 2012. The number of diagnoses of stage I non-small cell lung cancer steadily increased over the 15-year period, whereas the rate of lobectomy decreased from 55% in 1998 to 50% in 2012 (P < .001). Most of the decrease in lobectomy can be explained by the increase in the rate of sublobar resection from 12% to 17% (P < .001). The percentage of untreated patients remained stable at approximately 7% (P = .283). CONCLUSIONS: Although the number of stage I non-small cell lung cancer cases continues to increase, lobectomy rates are decreasing while sublobar resection and stereotactic body radiation therapy rates are increasing. Although the increasing popularity of alternative therapies to lobectomy for treatment of stage I non-small cell lung cancer should allow more patients to undergo treatment, we did not observe this trend in the data.
引用
- McMurry TL, Shah PM, Samson P, et al. Treatment of stage I non-small cell lung cancer: What's trending? J Thorac Cardiovasc Surg. 2017. PMID: 28476421. doi:10.1016/j.jtcvs.2017.03.122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。